Editorial comment
Low-density lipoprotein cholesterol lowering in the comfort zone and the benefits of stepping out
Saindo da zona de conforto para obter mais benefícios da redução do colesterol das LDL
Carlos Aguiar
Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Carnaxide, Portugal
Lido
2289
Vezesque se leu este artigo
916
Total PDF
1373
Total HTML
Compartilhar estatísticas
array:24 [ "pii" => "S087025512200213X" "issn" => "08702551" "doi" => "10.1016/j.repc.2022.05.001" "estado" => "S300" "fechaPublicacion" => "2022-08-01" "aid" => "1962" "copyright" => "Sociedade Portuguesa de Cardiologia" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "dis" "cita" => "Rev Port Cardiol. 2022;41:689-91" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S087025512200261X" "issn" => "08702551" "doi" => "10.1016/j.repc.2021.09.013" "estado" => "S300" "fechaPublicacion" => "2022-08-01" "aid" => "1981" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "rev" "cita" => "Rev Port Cardiol. 2022;41:693-703" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review Article</span>" "titulo" => "Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "693" "paginaFinal" => "703" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Mavacamten, uma nova terapia revolucionária na miocardiopatia hipertrófica obstrutiva: uma revisão de literatura" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2688 "Ancho" => 2512 "Tamanyo" => 803272 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Summary of mavacamten's translational research path. LVOT: left ventricular outflow tract; LVOTO: left ventricular outflow tract obstruction; LVH: left ventricular hypertrophy; QoL: quality of life; T0-T2: translational research layers.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Tiago Aguiar, Elisabete Martins" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Tiago" "apellidos" => "Aguiar" ] 1 => array:2 [ "nombre" => "Elisabete" "apellidos" => "Martins" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S087025512200261X?idApp=UINPBA00004E" "url" => "/08702551/0000004100000008/v2_202209110531/S087025512200261X/v2_202209110531/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0870255122001664" "issn" => "08702551" "doi" => "10.1016/j.repc.2021.05.017" "estado" => "S300" "fechaPublicacion" => "2022-08-01" "aid" => "1946" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Cardiol. 2022;41:681-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Long-term outcomes of primary cardiovascular prevention: A retrospective study at a referral center in Portugal" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "681" "paginaFinal" => "688" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Resultados a longo prazo da prevenção cardiovascular primária: estudo retrospetivo num centro de referência em Portugal" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1677 "Ancho" => 2500 "Tamanyo" => 254022 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Study design and patient distribution over the follow-up period (median: 11.0 years). CVD: cardiovascular disease; Lp(a): lipoprotein(a); MACE: major adverse cardiovascular events.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Joaquim A. Meireles-Brandão, Lúcia R. Meireles-Brandão, Rui Coelho, Francisco Rocha-Gonçalves" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Joaquim A." "apellidos" => "Meireles-Brandão" ] 1 => array:2 [ "nombre" => "Lúcia R." "apellidos" => "Meireles-Brandão" ] 2 => array:2 [ "nombre" => "Rui" "apellidos" => "Coelho" ] 3 => array:2 [ "nombre" => "Francisco" "apellidos" => "Rocha-Gonçalves" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255122001664?idApp=UINPBA00004E" "url" => "/08702551/0000004100000008/v2_202209110531/S0870255122001664/v2_202209110531/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial comment</span>" "titulo" => "Low-density lipoprotein cholesterol lowering in the comfort zone and the benefits of stepping out" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "689" "paginaFinal" => "691" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Carlos Aguiar" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Carlos" "apellidos" => "Aguiar" "email" => array:1 [ 0 => "ctaguiar@gmail.com" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Carnaxide, Portugal" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Saindo da zona de conforto para obter mais benefícios da redução do colesterol das LDL" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Atherosclerosis is the most common pathophysiologic process leading to cardiovascular disease (CVD). In 2016, an estimated 15 123 deaths in mainland Portugal were attributable to ischemic heart disease, ischemic cerebrovascular disease, or peripheral arterial disease, which corresponded to 14.3% of overall mortality. In the same year, disability-adjusted life years attributable to atherosclerosis totaled 260 943, of which 75% were due to premature death (196 438 years of life lost) and 25% due to disability (64 505 years lived with disability).<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Plasma lipid abnormalities by themselves may be responsible for as many as 50% of myocardial infarctions and 25% of strokes. Lowering low-density lipoprotein cholesterol (LDL-C), the primary driver of atherogenesis, reduces the risk of major vascular events. Statins, ezetimibe, and PCSK9 inhibitors have biologically equivalent effects on the risk of vascular events per unit change in LDL-C. The clinical benefit of these interventions depends on the absolute magnitude of the achieved LDL-C reduction and the total duration of treatment. In short, lower is better, and so is longer.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">2</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Pharmacologic lowering of LDL-C is safe. The risk of serious muscle injury, including rhabdomyolysis, is <0.1%, and the risk of serious hepatotoxicity is about 0.001%. Newly diagnosed diabetes occurs at a rate of about 0.2% per year of treatment, and there is no convincing evidence for a causal relationship between statins and cancer, cataracts, cognitive dysfunction, peripheral neuropathy, erectile dysfunction, or tendonitis.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">3</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">LDL-C lowering is also cost-effective, even more so with the advent of generic pricing. Accordingly, it has been suggested that eligibility for preventive statin therapy should be expanded to younger individuals and that treating patients at borderline risk regardless of LDL-C level would likely be highly cost-effective.<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">4,5</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Over the past decade, several observational studies have reported the LDL-C levels of patients receiving lipid-lowering therapy in Portugal (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). These reports indicate that LDL-C levels are above the recommended goals in most patients eligible for pharmacologic LDL-C lowering, and the rates of LDL-C control have not improved over time. An additional reason for concern is the significant number of patients eligible for LDL-C lowering therapy who are not receiving any treatment.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">In this issue of the <span class="elsevierStyleItalic">Journal</span>, Meireles-Brandão et al. report the results of the ISTO study, which provides further evidence on the control of LDL-C in primary prevention patients living in Portugal.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">12</span></a> ISTO is a retrospective study of 516 patients managed at a CVD risk outpatient clinic in a university hospital. Study patients had at least two CVD risk factors and were followed for at least two years between 1995 and 2015. At baseline, 75.0% of patients were overweight or obese, 71.9% were not regularly physically active, 63.8% had a history of hypertension, 30.6% had diabetes, and 13.0% were current smokers. Moderate-intensity statin therapy was prescribed for 91.5% of patients at baseline and intended to be maintained throughout follow-up. At a median follow-up of 11 years, median LDL-C levels had improved significantly, from 172 mg/dl at baseline to 92 mg/dl at last follow-up. This change was associated with significant reductions in both median carotid intima-media thickness and CVD risk at last follow-up. Nevertheless, since most patients had high CVD risk at baseline (according to the Framingham risk score or the ASCVD risk estimator) and considering the wide range of LDL-C levels at last follow-up, from 37 mg/dl to 211 mg/dl, it seems reasonable to conclude that most patients had not achieved currently recommended LDL-C goals at last follow-up.</p><p id="par0035" class="elsevierStylePara elsevierViewall">The findings of the ISTO study, like previous studies performed in Portugal, are not surprising. Most of the patients receiving lipid-lowering therapy in these studies were on moderate-intensity statin therapy and very few were taking ezetimibe. Taking a statin is certainly not enough to prevent avoidable atherosclerotic CVD. Optimal lowering of LDL-C is not achieved in most patients initiated on statin monotherapy, and these patients will experience significantly increased risk of future CVD, whether or not established CVD is present at baseline.<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">13,14</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">Now is the time to step out of the comfort zone, to fight treatment inertia and realize the full potential of the benefits of LDL-C reduction in patients at high or very high CVD risk, by combining statin therapy with ezetimibe and/or other LDL-C lowering therapies such as bempedoic acid and PCSK9 inhibitors as needed to achieve the recommended LDL-C goal.<span class="elsevierStyleDisplayedQuote" id="dsq0005"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">“Great things never came from comfort zones.” (Neil Strauss)</p></span></p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of interest</span><p id="par0045" class="elsevierStylePara elsevierViewall">The author declares having received honoraria for consultancy and/or lectures from Amgen, Daiichi-Sankyo, Medinfar, Novartis, Tecnimede, and Viatris.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflicts of interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">CVD: cardiovascular disease; LDL-C: low-density lipoprotein cholesterol.</p>" "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Study \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Study population \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Results \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">VALSIM<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">6</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 856 patients followed by 719 primary care physicians, 2006-2007 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12.8% of statin-treated patients had both total cholesterol ≤175 mg/dl and LDL-C<100 mg/dl \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DYSIS-Portugal<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">7</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">916 patients, age ≥45 years, on statin treatment, 2008-2009 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">37.1% of the (very) high CVD risk subgroup of patients had LDL-C<100 mg/dl \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DISGEN-LIPID<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">8</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">368 patients, age ≥40 years, on lipid-lowering therapy, 2014-2015 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">46.7% of patients with either diabetes or established CVD had LDL-C<70 mg/dl \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">EUROASPIRE V<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">9</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">295 patients, age <80 years, with history of coronary revascularization or acute coronary syndrome, 2016-2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30.1% of patients had LDL-C<70 mg/dl \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PRECISE<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">10</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2848 hypertensive patients followed by primary care physicians (1612 on lipid-lowering therapy) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">37.7% of patients on lipid-lowering therapy had total cholesterol<190 mg/dl \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Araújo et al.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">11</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1314 very high CVD risk patients admitted to a cardiology department (871 on lipid-lowering therapy), 2011/2012 and 2016/2017 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24.4% of patients had LDL-C<70 mg/dl \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Observational studies reporting total cholesterol and/or low-density lipoprotein cholesterol levels achieved with lipid-lowering therapy in Portugal.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:14 [ 0 => array:3 [ "identificador" => "bib0075" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The burden of atherosclerosis in Portugal" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Costa" 1 => "J. Alarcão" 2 => "F. Araújo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ehjqcco/qcaa060" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J Qual Care Clin Outcomes" "fecha" => "2021" "volumen" => "7" "paginaInicial" => "154" "paginaFinal" => "162" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32946553" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0080" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B.A. Ference" 1 => "C.P. Cannon" 2 => "U. Landmesser" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehx450" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2018" "volumen" => "39" "paginaInicial" => "2540" "paginaFinal" => "2545" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29020411" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0085" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Statin safety and associated adverse events: a scientific statement from the American Heart Association" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C.B. Newman" 1 => "D. Preiss" 2 => "J.A. Tobert" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/ATV.0000000000000073" "Revista" => array:6 [ "tituloSerie" => "Arterioscler Thromb Vasc Biol" "fecha" => "2019" "volumen" => "39" "paginaInicial" => "e38" "paginaFinal" => "e81" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30580575" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0090" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost-effectiveness of lipid-lowering treatments in young adults" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C.N. Kohli-Lynch" 1 => "B.K. Bellows" 2 => "Y. Zhang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2021.08.065" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2021" "volumen" => "78" "paginaInicial" => "1954" "paginaFinal" => "1964" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34763772" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0095" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost-effectiveness of low-density lipoprotein cholesterol level-guided statin treatment in patients with borderline cardiovascular risk" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C.N. Kohli-Lynch" 1 => "B.K. Bellows" 2 => "G. Thanassoulis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamacardio.2019.2851" "Revista" => array:6 [ "tituloSerie" => "JAMA Cardiol" "fecha" => "2019" "volumen" => "4" "paginaInicial" => "969" "paginaFinal" => "977" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31461121" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0100" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Characterization of lipid profile in primary health care users in Portugal" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "on behalf of the VALSIM Study Investigators" "etal" => true "autores" => array:3 [ 0 => "N. Cortez-Dias" 1 => "S.R. Martins" 2 => "A. Belo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.repc.2013.06.008" "Revista" => array:6 [ "tituloSerie" => "Rev Port Cardiol" "fecha" => "2013" "volumen" => "32" "paginaInicial" => "987" "paginaFinal" => "996" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24280078" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0105" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS)" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "on behalf of the DYSIS-Portugal Study Investigators" "etal" => false "autores" => array:2 [ 0 => "P.M. Silva" 1 => "S.M. Cardoso" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Rev Port Cardiol" "fecha" => "2011" "volumen" => "30" "paginaInicial" => "47" "paginaFinal" => "63" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21425743" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0007091217303665" "estado" => "S300" "issn" => "00070912" ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0110" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: data from the DISGEN-LIPID study" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "for the DISGEN-LIPID Study Investigators" "etal" => false "autores" => array:3 [ 0 => "P.M. Silva" 1 => "C. Aguiar" 2 => "J. Morais" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Port Cardiol" "fecha" => "2019" "volumen" => "38" "paginaInicial" => "559" "paginaFinal" => "569" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0115" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "on behalf of the EUROASPIRE Investigators" "etal" => true "autores" => array:3 [ 0 => "K. Kotseva" 1 => "G. De Backer" 2 => "D. De Bacquer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/2047487318825350" "Revista" => array:6 [ "tituloSerie" => "Eur J Prev Cardiol" "fecha" => "2019" "volumen" => "26" "paginaInicial" => "824" "paginaFinal" => "835" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30739508" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0120" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of cardiovascular risk factors and other comorbidities in patients with hypertension in Portuguese primary health care populations: the PRECISE study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "P.M. Silva" 1 => "M.J. Lima" 2 => "P.M. Neves" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.repc.2018.09.011" "Revista" => array:6 [ "tituloSerie" => "Rev Port Cardiol" "fecha" => "2019" "volumen" => "38" "paginaInicial" => "427" "paginaFinal" => "437" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31307727" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0125" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temporal trends of lipid control in very high cardiovascular risk patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "P.M. Araújo" 1 => "A. Nunes" 2 => "S. Torres" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.repce.2020.10.021" "Revista" => array:6 [ "tituloSerie" => "Rev Port Cardiol" "fecha" => "2021" "volumen" => "40" "paginaInicial" => "641" "paginaFinal" => "648" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34503701" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0130" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term outcomes of primary cardiovascular prevention: a retrospective study at a referral center in Portugal" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J.A. Meireles-Brandão" 1 => "L.R. Meireles-Brandão" 2 => "R. Coelho" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Port Cardiol" "fecha" => "2022" "volumen" => "41" "paginaInicial" => "671" "paginaFinal" => "678" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0135" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quantifying unmet need in statin-treated hyperlipidemia patients and the potential benefit of further LDL-C reduction through an EHR-based retrospective cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "T. Schleyer" 1 => "S. Hui" 2 => "J. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.18553/jmcp.2019.25.5.544" "Revista" => array:6 [ "tituloSerie" => "J Manag Care Spec Pharm" "fecha" => "2019" "volumen" => "25" "paginaInicial" => "544" "paginaFinal" => "554" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31039062" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0140" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S.F. Weng" 1 => "R.K. Akyea" 2 => "K.K. Man" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0260839" "Revista" => array:5 [ "tituloSerie" => "PLoS One" "fecha" => "2021" "volumen" => "16" "paginaInicial" => "e0260839" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34855879" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/08702551/0000004100000008/v2_202209110531/S087025512200213X/v2_202209110531/en/main.assets" "Apartado" => array:4 [ "identificador" => "92834" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original Articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/08702551/0000004100000008/v2_202209110531/S087025512200213X/v2_202209110531/en/main.pdf?idApp=UINPBA00004E&text.app=https://www.revportcardiol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S087025512200213X?idApp=UINPBA00004E" ]
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2024 Outubro | 29 | 29 | 58 |
| 2024 Setembro | 49 | 25 | 74 |
| 2024 Agosto | 93 | 46 | 139 |
| 2024 Julho | 47 | 41 | 88 |
| 2024 Junho | 39 | 33 | 72 |
| 2024 Maio | 40 | 17 | 57 |
| 2024 Abril | 29 | 36 | 65 |
| 2024 Maro | 33 | 27 | 60 |
| 2024 Fevereiro | 30 | 31 | 61 |
| 2024 Janeiro | 30 | 38 | 68 |
| 2023 Dezembro | 19 | 28 | 47 |
| 2023 Novembro | 47 | 37 | 84 |
| 2023 Outubro | 22 | 24 | 46 |
| 2023 Setembro | 25 | 27 | 52 |
| 2023 Agosto | 43 | 11 | 54 |
| 2023 Julho | 29 | 16 | 45 |
| 2023 Junho | 37 | 16 | 53 |
| 2023 Maio | 63 | 32 | 95 |
| 2023 Abril | 61 | 13 | 74 |
| 2023 Maro | 71 | 30 | 101 |
| 2023 Fevereiro | 72 | 26 | 98 |
| 2023 Janeiro | 38 | 16 | 54 |
| 2022 Dezembro | 58 | 23 | 81 |
| 2022 Novembro | 37 | 34 | 71 |
| 2022 Outubro | 51 | 27 | 78 |
| 2022 Setembro | 46 | 52 | 98 |
| 2022 Agosto | 110 | 104 | 214 |
| 2022 Julho | 76 | 46 | 122 |
| 2022 Junho | 49 | 31 | 80 |
Mostrar tudo
